Search for stock quotes, financial statistics and more
Raymond James analyst David Novak is slightly clipping his estimate of Knight Therapeutics (Knight T... Read More
Stifel GMP Analyst Justin Keywood is still riding high with Knight Therapeutics (Knight Therapeutics... Read More
Paradigm Capital analyst Scott McAuley makes the case for investing in Canadian pharmaceutical compa... Read More
Biopharmaceutical stocks had their ups and downs over 2021 but volatility in the sector is par for t... Read More
Paradigm Capital Markets analyst Scott McAuley is still a fan of Knight Therapeutics (Knight Therap... Read More
Share
Tweet
pin
Share